Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Genetic clues to severe preeclampsia could transform early detection

NCT ID NCT07703826

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study investigates genetic and molecular markers in pregnant women with severe preeclampsia, a dangerous condition involving high blood pressure and organ damage. Researchers will analyze blood, urine, and placental samples from 100 women to identify changes in genes and cell types that distinguish severe cases from healthy pregnancies. The goal is to improve early screening and understand the biological roots of the condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could identify early screening markers for severe preeclampsia and uncover its underlying causes.
What could go wrong
This is an observational study with a small sample size (100 participants), so findings may not apply broadly and require further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

100 pregnant women recruited at a single center. Participants will be divided into two groups: 50 pregnant women diagnosed with severe preeclampsia and 50 healthy pregnant women without any pregnancy-related pathology serving as the control group. Biological samples and clinical data will be collected at enrollment to identify genetic and molecular markers associated with severe preeclampsia.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion criteria for patients in the experimental group P: \- Pregnant women between 18 and 45 years old, between 24 and 41 weeks of amenorrhea (WA), with severe preeclampsia defined according to the criteria of the joint expert recommendations of the French National College of Gynecologists and Obstetricians (CNGOF) and the French Society of Anesthesia and Intensive Care (SFAR) from 2020 "Management of the patient with severe preeclampsia." These criteria are: gestational hypertension with systolic ≥ 140 mmHg and/or diastolic ≥ 90 mmHg, and proteinuria ≥ 0.3g/24h, plus at least one of the following severity criteria: * Severe hypertension (SBP ≥ 160 mmHg and/or DBP ≥ 110 mmHg) or uncontrolled. * Proteinuria \> 3g/24h. * Creatinine ≥ 90 μmol/L. * Oliguria ≤ 500 mL/24h or ≤ 25 mL/h. * Thrombocytopenia \< 100,000/mm3 * Liver enzyme elevation with AST/ALT \>2x normal. * Epigastric abdominal pain and/or persistent or severe right upper quadrant pain "like a band." * Chest pain, shortness of breath, acute pulmonary edema. * Neurological signs: severe headaches not responding to treatment, persistent visual or auditory disturbances, hyperactive, widespread, and polykinetic tendon reflexes. * Patient's free and informed consent regarding the collection of maternal blood and urine. * Consent from both legal guardians regarding the collection of cord blood, placenta samples, and newborn data. Inclusion criteria for patients in the control group: * Pregnant women between 18 and 45 years old and between 24 and 41 weeks of gestation, with a pregnancy without any complications * Free and informed consent from the patient regarding the collection of maternal blood and urine * Consent from both holders of parental authority regarding the collection of cord blood, placental fragments, and newborn data Exclusion Criteria: EXCLUSION CRITERIA: for all patients * Diabetes prior to pregnancy * Multiple pregnancy * Long-term medication treatment (except usual pregnancy supplements) * Smoking, alcohol, or drug use during pregnancy * Pre-existing liver, kidney, or heart failure * History of bariatric surgery * Neonatal acidosis with arterial cord pH below 7.0 (rare event) * Genetic or chromosomal abnormality of the mother and/or newborn diagnosed prenatally * Fetal malformation diagnosed prenatally * Refusal to participate in the study * Person unable to consent or under protection (guardianship, curatorship) * Minor * Inability to participate in the entire study Exclusion criteria for patients in the control group T: For women in the control group, any obstetric condition (apart from delivery complications).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Preeclampsia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.